Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations
Nathan WD Lamond, Tallal YounisDepartment of Medicine, Dalhousie University at the Queen Elizabeth II Health Sciences Centre, Halifax, NS, CanadaAbstract: In the absence of specific therapy, the 15%–20% of breast cancers demonstrating human epidermal growth-factor receptor 2 (HER2) protei...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2014-05-01
|
| Series: | International Journal of Women's Health |
| Online Access: | http://www.dovepress.com/pertuzumab-in-human-epidermal-growth-factor-receptor-2-positive-breast-a16873 |